U.S. Patent Granted For Tonix Pharma's Zembrace® Migraine Treatment

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company with both marketed products and a robust development pipeline, announced today that it has been granted U.S. Patent No. 12,097,183 by the United States Patent and Trademark Office. The patent titled "Pharmaceutical Composition for Treating Migraine"  involves a pre-filled autoinjector device containing Zembrace ® SymTouch ® for subcutaneously treating migraines. This patent is expected to continue throughout 2036 unless additional rights are extended.

An educational campaign has been launched recently by Tonix Pharma called "Does Your Migraine Pill Work Every Time?" — which educates patients and healthcare providers about the benefits of non-oral treatments for migraines, specifically nasal sprays and injectables. These alternative routes are absorbed directly into the body, bypassing the first-pass metabolism, which may allow for faster relief of migraine symptoms, sometimes taking up as little as 10 minutes.

Patients who suffer with the problem of migraine often need to take an active role in shaping their treatment plans. By providing them with the knowledge to recognize why oral medications may not always provide timely or consistent relief and introducing them to alternative treatment options, they will be able to manage their symptoms in a better way. This empowerment can lead to more effective migraine control and an overall improvement in their quality of life. 

Migraine sufferers often experience gastroparesis, a condition that can occur before, during, or even between migraine episodes. This condition slows down or prevents the body from properly absorbing oral medications, which can lead to delayed or incomplete relief from migraine symptoms. 

Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, said in a statement, “We are excited to announce the issuance of this additional patent, providing additional protection for our exclusive marketing and sale of FDA-approved Zembrace® for the treatment of migraines. We believe Zembrace® is a compelling non-oral option for people who suffer from migraines.”

He further added, “Tonix is dedicated to educating patients and their healthcare providers on gastroparesis and how non-oral medicines, including nasal and injectable medications, can help patients manage their migraines. We hope to inspire patients to optimise their migraine treatment plan with non-oral medications.”